Mechanisms of immune escape and extramedullary tropism in leukemia cutis

L Livius Penter K Katie Maurer N Nicoletta Cieri (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) W Wesley S. Lu (6Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA) H Haoxiang Lyu (2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA) M Mischa Selig (2Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow-Klinikum, Berlin, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany) M Maria Joosten J Jana Ihlow (2Institute of Pathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany) S Shuqiang Li K Kenneth J. Livak L Lars Bullinger J Jerome Ritz (Dana–Farber Cancer Institute, Boston) P Pavan Bachireddy (8MD Anderson Cancer Center, Houston, TX) M Matthew S. Davids (1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA) J Jacqueline S. Garcia (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) R Robert J. Soiffer (Dana-Farber Cancer Institute) C Catherine J. Wu

Abstract

Abstract The mechanisms that lead to extramedullary tropism of acute myeloid leukemia (eAML) remain obscure and no specific therapeutic approaches for this entity exist. Because the long-term survival of eAML is poor, a deeper understanding of the immune microenvironment and leukemia phenotypes underlying this entity is warranted. Here, we performed bulk and single-cell transcriptome profiling of 23 eAML biopsies from 10 patients with isolated extramedullary disease in skin and subcutaneous tissue. Unlike normal healthy skin, we found leukemia cutis to be heavily immune infiltrated; in extramedullary relapse after allogeneic stem cell transplantation, >90% of T/natural killer cells were donor derived. eAML-associated T cells expressed a clear signature of T-cell exhaustion, dissimilar to leukemia-associated immune populations in bone marrow relapse (n = 7) but related to acute and chronic skin inflammation. Furthermore, HLA class II was downregulated in 4 of 7 leukemia cutis specimens, consistent with an immune escape phenotype in eAML. Extramedullary and bone marrow–resident leukemia cells differed with regard to the expression of 8 homing receptor molecules (ICAM1 [encoding CD54], PECAM1 [CD31], ITGA4, ITGA6, ITGAL, ITGB4, ITGA5, and ITGAV). Serial samples obtained from 1 leukemia cutis throughout consecutive immune checkpoint blockade with ipilimumab followed by nivolumab showed a consistently high degree of overlap between local and circulating T-cell receptor sequences, suggesting that only a minority of eAML-associated T cells are leukemia specific. Our analysis reveals eAML to associate with complex changes in leukemia and T-cell gene expression profiles that suggest multiple potential avenues for therapeutic targeting.

Article Details

Journal Blood
Volume / Issue Vol. 147, Issue 1
Published January 01, 2026
Pages 35-47
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (17)

L

Livius Penter

K

Katie Maurer

N

Nicoletta Cieri

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

W

Wesley S. Lu

6Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA

H

Haoxiang Lyu

2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

M

Mischa Selig

2Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow-Klinikum, Berlin, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

M

Maria Joosten

J

Jana Ihlow

2Institute of Pathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

S

Shuqiang Li

K

Kenneth J. Livak

L

Lars Bullinger

J

Jerome Ritz

Dana–Farber Cancer Institute, Boston

P

Pavan Bachireddy

8MD Anderson Cancer Center, Houston, TX

M

Matthew S. Davids

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

J

Jacqueline S. Garcia

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

R

Robert J. Soiffer

Dana-Farber Cancer Institute

C

Catherine J. Wu